TELO Telomir Pharmaceuticals Inc

Price (delayed)

$0.4231

Market cap

$31.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.89

Enterprise value

$26.73M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 8

Telomir Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small ...

Highlights
The company's net income has surged by 51% YoY and by 7% QoQ
Telomir Pharmaceuticals's debt has decreased by 50% from the previous quarter
Telomir Pharmaceuticals's EPS has shrunk by 141% YoY but it has increased by 2.2% QoQ
Telomir Pharmaceuticals's equity has decreased by 37% YoY and by 12% QoQ

Key stats

What are the main financial stats of TELO

TELO stock price

How has the Telomir Pharmaceuticals stock price performed over time
Intraday
-12.04%
1 week
-26.04%
1 month
-59.7%
1 year
-69.78%
YTD
-68.19%
QTD
-64.74%

Financial performance

How have Telomir Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$5.69M
Net income
-$5.48M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 51% YoY and by 7% QoQ
TELO's operating income is up by 50% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does TELO's price correlate with its fundamentals

Growth

What is Telomir Pharmaceuticals's growth rate over time

Valuation

What is Telomir Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Telomir Pharmaceuticals's EPS has shrunk by 141% YoY but it has increased by 2.2% QoQ
The price to book (P/B) is 43% less than the last 4 quarters average of 13.2
Telomir Pharmaceuticals's equity has decreased by 37% YoY and by 12% QoQ

Efficiency

How efficient is Telomir Pharmaceuticals business performance
The return on assets has dropped by 99% year-on-year and by 11% since the previous quarter
The ROE has plunged by 79% YoY and by 12% from the previous quarter

Dividends

What is TELO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TELO.

Financial health

How did Telomir Pharmaceuticals financials performed over time
TELO's total liabilities is down by 44% year-on-year and by 29% since the previous quarter
The total assets has declined by 37% year-on-year and by 14% since the previous quarter
Telomir Pharmaceuticals's debt is 98% less than its equity
Telomir Pharmaceuticals's debt has decreased by 50% from the previous quarter
Telomir Pharmaceuticals's equity has decreased by 37% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.